Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/Tuvonralimab + Bevacizumab in Advanced Melanoma
NCT07004335Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of iparomlimab, tuvonralimab in melanoma, sponsored by The Fourth Hospital of Hebei Medical University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07004335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004335.